Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Indication: Enfortumab Vedotin for Head and Neck Cancer
Open-label, multicohort, phase II study (EV-202) Recurrent/metastatic head and neck cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors Enfortumab
New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab
Phase 3, multicenter, open-label, randomized trial (AMPLIFY) Previously untreated CLL without del(17p) or TP53 mutation Acalabrutinib–venetoclax vs. acalabrutinib–venetoclax–
New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer
Phase 2, open-label, multicenter clinical trial (eNRGy) Advanced/metastatic solid tumors with NRG1 fusion Zenocutuzumab 750 mg IV every 2 weeks
New Protocol: Ipilimumab + Nivolumab for MSI-H Colorectal Cancer
Phase 3, multicenter, open-label, randomized clinical trial (CheckMate 8HW) Unresectable or metastatic colorectal cancer with MSI-H/dMMR status, across all treatment lines Nivoluma
New Reference: Trastuzumab Emtansine in HER2-Positive Breast Cancer with Residual Disease
Phase 3, multicenter, randomized, controlled trial (KATHERINE) HER2-positive early breast cancer with residual invasive cancer after neoadjuvant therapy T-DM1 vs. trastuzumab (14 c
New Reference: Periop FLOT in Esophageal Cancer
Phase 3, multicenter, randomized, controlled trial (ESOPEC) Esophageal or GE junction adenoCa, cT1cN+, cT2–4a cN+, or cT2–4a cN0 FLOT (perioperative chemotherapy) vs. preoperat
New Drug: Datopotamab Deruxtecan for HR+, her2 Neg Breast Cancer
Phase 3, open-label, randomized study (TROPION-Breast01) Inoperable or metastatic HR+/HER2– breast cancer, previously treated with 1 or 2 lines of chemotherapy in the inoperable/
New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma
Randomized, double-blind, placebo-controlled, multicenter trial (ECHO) Previously untreated Mantle Cell Lymphoma (MCL) who were ineligible for transplant (N=598) Acalabrutinib + R-
New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer
Multi-center, open lavel study (eNRGy) NRG1 fusion positive NSCLC (n=64) and pancreatic adenocarcinoma (n=30) with disease progression after standard therapy
